Ven­rock stocks up on $450M Fund 8 as it pre­pares a new string of biotech deals

The ven­ture part­ners at Ven­rock have an ap­petite for high-risk biotechs look­ing to break new ground. Now they have a new $450 mil­lion fund to sat­is­fy them­selves with a steady di­et of new deals ahead.

Bryan Roberts, a part­ner spe­cial­iz­ing in health­care who was in on Re­cep­tos ear­ly on — well be­fore Cel­gene ac­quired it for $7.2 bil­lion — used a blog post on the VC’s site to an­nounce the new fund, Ven­rock’s 8th. He wrote:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.